CD274 and prostate carcinoma: Rahouma et al. performed a meta-analysis of 11 anti-PD/PD-L1 immunotherapy randomized clinical trials (seven melanoma RCTs, three non-small-cell lung cancer RCTs, and one prostate cancer,) including five studies comparing mono-immunotherapy to chemotherapy, which showed that cardiotoxicity was statistically insignificant (RR: 1.15; 95% CI: 0.73–1.80; p = 0.55) regardless the treatment regimen; either chemotherapy or dual immunotherapy [22].